Skip to content
Part of the HERE CITY NETWORK Wednesday, November 18, 2026

National Deal News from the HERE CITY Network

Mergers & Acquisitions

Lilly to Buy Calytrix Bio for Up to $1.5 Billion

Eli Lilly agreed to buy private biotech Calytrix Bio for up to $1.5 billion in cash, adding a preclinical antibody for rare blood cancers to its pipeline.

Eli Lilly & Co. agreed to buy Calytrix Bio Inc. for up to $1.5 billion in cash, extending one of the busiest acquisition runs in the drug industry with a bet on a medicine that has not yet reached human trials.

Calytrix, based in Wellesley Hills, Mass., announced the deal Monday. Its shareholders will receive an upfront payment plus additional amounts if the program hits certain clinical and regulatory milestones, with the total capped at $1.5 billion. Neither side disclosed the upfront amount or an expected closing date. Lilly shares rose about 1.4% in early trading.

Targeting the mutation

Calytrix is developing a biparatopic antibody that binds two sites on mutant calreticulin, a protein that drives essential thrombocythemia and myelofibrosis. The two diseases are myeloproliferative neoplasms, slow-growing blood cancers in which bone marrow produces too many abnormal cells. Current drugs mostly manage symptoms, and the company is designing its antibody to clear the mutant cell population while sparing healthy blood-forming cells, with a safety profile meant to allow early and long-term treatment.

The company was founded in 2025 by J.P. Morgan Life Sciences Private Capital, the venture arm of J.P. Morgan Asset Management, which co-led its Series A with Westlake BioPartners. Avoro Ventures led a later Series B.

Fifteen deals and counting

The purchase adds to a hematology business that already includes the approved blood cancer drug Jaypirca and follows the $2.3 billion purchase of Ajax Therapeutics earlier this year, another blood cancer bet. By one industry count, Lilly has now spent more than $30 billion on 15 company acquisitions in 2026, the majority of them private startups, far ahead of GSK, Gilead Sciences and Novartis at three apiece.

The deal landed the same day Johnson & Johnson agreed to buy Ollin Biosciences, another private biotech sold before its lead drug finished development. Paul, Weiss advised Lilly.

Sources

  1. prnewswire.com
  2. biopharmadive.com
  3. biospace.com
  4. investing.com

biotech blood cancer calytrix bio eli lilly jp morgan massachusetts mergers acquisitions myelofibrosis